Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Educational Report
  • Published:

Acute Leukemias

Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983–2002: A Children's Oncology Group Report

Abstract

The Children's Cancer Group enrolled 13 298 young people age <21 years on 1 of 16 protocols between 1983 and 2002. Outcomes were examined in three time periods, 1983–1988, 1989–1995, 1996–2002. Over the three intervals, 10-year event-free survival (EFS) for Rome/National Cancer Institute standard risk (SR) and higher risk (HR) B-precursor patients was 68 and 58%, 77 and 63%, and 78 and 67%, respectively, whereas for SR and HR T-cell patients, EFS was 65 and 56%, 78 and 68%, and 70 and 72%, respectively. Five-year EFS for infants was 36, 38, and 43%, respectively. Seminal randomized studies led to a number of important findings. Stronger post-induction intensification improved outcome for both SR and HR patients. With improved systemic therapy, additional intrathecal (IT) methotrexate effectively replaced cranial radiation. For SR patients receiving three-drug induction, iso-toxic substitution of dexamethasone for prednisone improved EFS. Pegylated asparaginase safely and effectively replaced native asparaginase. Thus, rational therapy modifications yielded better outcomes for both SR and HR patients. These trials provide the platforms for current Children's Oncology Group trials.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Pinkel D, Simone J, Hustu HO, Aur RJ . Nine years' experience with ‘total therapy’ of childhood acute lymphocytic leukemia. Pediatrics 1972; 50: 246–251.

    CAS  Google Scholar 

  2. Henze G, Langermann HJ, Bramswig J, Breu H, Gadner H, Schellong G et al. The BFM 76/79 acute lymphoblastic leukemia therapy study (author's transl). Klin Padiatr 1981; 193: 145–154.

    Article  CAS  Google Scholar 

  3. Bleyer WA, Coccia PF, Sather HN, Level C, Lukens J, Niebrugge DJ et al. Reduction in central nervous system leukemia with a pharmacokinetically derived IT methotrexate dosage regimen. J Clin Oncol 1983; 1: 317–325.

    Article  CAS  Google Scholar 

  4. Miller DR, Leikin S, Albo V, Sather H, Karon M, Hammond D . Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG-141. A report from the Children's Cancer Study Group. Cancer 1983; 51: 1041–1049.

    Article  CAS  Google Scholar 

  5. Bleyer WA, Sather HN, Nickerson HJ, Coccia PF, Finklestein JZ, Miller DR et al. Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: a report of the CCG-161 study by the Childrens Cancer Study Group. J Clin Oncol 1991; 9: 1012–1021.

    Article  CAS  Google Scholar 

  6. Gaynon PS, Trigg ME, Heerema NA, Sensel MG, Sather HN, Hammond GD et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 2000; 14: 2223–2233.

    Article  CAS  Google Scholar 

  7. Gaynon PS, Steinherz PG, Bleyer WA, Ablin AR, Albo VC, Finklestein JZ et al. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106. J Clin Oncol 1993; 11: 2234–2242.

    Article  CAS  Google Scholar 

  8. Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH et al. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group. Cancer 1998; 82: 600–612.

    Article  CAS  Google Scholar 

  9. Tubergen DG, Gilchrist GS, O'Brien RT, Coccia PF, Sather HN, Waskerwitz MJ et al. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and IT methotrexate and the importance of systemic therapy: a Childrens Cancer Group report. J Clin Oncol 1993; 11: 520–526.

    Article  CAS  Google Scholar 

  10. Tubergen DG, Gilchrist GS, O'Brien RT, Coccia PF, Sather HN, Waskerwitz MJ et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. J Clin Oncol 1993; 11: 527–537.

    Article  CAS  Google Scholar 

  11. Nachman J, Sather HN, Cherlow JM, Sensel MG, Gaynon PS, Lukens JN et al. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group. J Clin Oncol 1998; 16: 920–930.

    Article  CAS  Google Scholar 

  12. Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998; 338: 1663–1671.

    Article  CAS  Google Scholar 

  13. Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2003; 101: 3809–3817.

    Article  CAS  Google Scholar 

  14. Stork L, Sather H, Hutchinson R, Broxson E, Matloub Y, Yanofsky R et al. Comparison of mercaptopurine (MP) with thioguanine (TG) and IT methotrexate (ITM) with IT ‘Triples’(ITT) in children with SR-ALL: results of CCG-1952. Blood 2002; 100: 585a.

    Article  Google Scholar 

  15. Matloub Y, Lindemulder S, Gaynon PS, Sather H, La M, Broxson E et al. IT triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with IT methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group. Blood 2006; 108: 1165–1173.

    Article  Google Scholar 

  16. Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2002; 99: 1986–1994.

    Article  CAS  Google Scholar 

  17. Seibel NL, Steinherz PG, Sather HN, Nachman JB, Delaat C, Ettinger LJ et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008; 111: 2548–2555.

    Article  CAS  Google Scholar 

  18. Matloub Y, Angiolillo A, Bostrom B, Hunger SP, Nachman J, Sather H et al. Double Delayed Intensification (DDI) is equivalent to single DI (SDI) in children with National Cancer Institute (NCI) standard-risk acute lymphoblatic leukemia (SR-ALL) treated on Children's Cancer Group (CCG) Clinical Trial 1991 (CCG-1991). Blood 2006; 108: 47a.

    Article  Google Scholar 

  19. Matloub Y, Bostrom BC, Hunger SP, Angiolillo AL, Cole C, Thomson B et al. Escalating dose intravenous methotrexate without leukovorin rescue during interim maintenance is superior to oral methotrexate for children with standard risk acute lymphoblastic leukemia (SR-ALL): a Children's Concology Group Study 1991. Blood 2008; 112: 9–10a.

    Google Scholar 

  20. Bennett J, Catovsky D, Daniel M, Flandrin G, Galton D, Gralnick H et al. Proposals for the classification of the acute leukaemias French-American-British (FAB) Co-operative Group. Br J Haematol 1976; 33: 451–458.

    Article  CAS  Google Scholar 

  21. Miller DR, Krailo M, Bleyer WA, Lukens JN, Siegel SE, Coccia PR et al. Prognostic implications of blast cell morphology in childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. Cancer Treat Rep 1985; 69: 1211–1221.

    CAS  Google Scholar 

  22. Steinherz PG, Siegel SE, Bleyer WA, Kersey J, Chard Jr R, Coccia P et al. Lymphomatous presentation of childhood acute lymphoblastic leukemia. A subgroup at high risk of early treatment failure. Cancer 1991; 68: 751–758.

    Article  CAS  Google Scholar 

  23. Lange BJ, Blatt J, Sather HN, Meadows AT . Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study. Med Pediatr Oncol 1996; 27: 15–20.

    Article  CAS  Google Scholar 

  24. Reaman GH, Sposto R, Sensel MG, Lange BJ, Feusner JH, Heerema NA et al. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. J Clin Oncol 1999; 17: 445–455.

    Article  CAS  Google Scholar 

  25. Hutchinson RJ, Gaynon PS, Sather H, Bertolone SJ, Cooper HA, Tannous R et al. Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children's Cancer Group Trial 1881. J Clin Oncol 2003; 21: 1790–1797.

    Article  Google Scholar 

  26. Lange BJ, Bostrom BC, Cherlow JM, Sensel MG, La MK, Rackoff W et al. Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2002; 99: 825–833.

    Article  CAS  Google Scholar 

  27. Smith M, Arthur D, Camitta B, Carroll A, Crist W, Gaynon P et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996; 14: 18–24.

    Article  CAS  Google Scholar 

  28. Heath JA, Steinherz PG, Altman A, Sather H, Jhanwar S, Halpern S et al. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study. J Clin Oncol 2003; 21: 1612–1617.

    Article  CAS  Google Scholar 

  29. Seibel N, Sather H, Steinherz P, De Laat C, Ettinger L, Freyer D . Upfront treatment with B43 PAP immunotoxin in newly diagnosed children with higher risk ALL–Children's Cancer Group 1961. Blood 2000; 96: 3115a.

    Google Scholar 

  30. Hilden JM, Dinndorf PA, Meerbaum SO, Sather H, Villaluna D, Heerema NA et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood 2006; 108: 441–451.

    Article  CAS  Google Scholar 

  31. Dreyer Z, Steuber C, Bowman W, Murray J, Dinndorf P, Camitta B . Induction intensification for infant acute lymphoid leukemia (ALL). Proc Am Soc Clin Oncol 1996; 15: 369a.

    Google Scholar 

  32. Dreyer Z, Dinndorf P, Sather H, Hilden J, Devidas M, Heerema N et al. Hematopoietic stem cell transplant (HSCT) versus intensive chemotherapy in infant acute lymphoblastic leukemia (ALL). Proc Am Soc Clin Oncol 2007; 25: 9514a.

    Google Scholar 

  33. Kaplan E, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  34. Gray R . A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141–1154.

    Article  Google Scholar 

  35. Satwani P, Sather H, Ozkaynak F, Heerema NA, Schultz KR, Sanders J et al. Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: a Children's Oncology Group study report. Biol Blood Marrow Transplant 2007; 13: 218–227.

    Article  CAS  Google Scholar 

  36. Conter V, Valsecchi MG, Silvestri D, Campbell M, Dibar E, Magyarosy E et al. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. Lancet 2007; 369: 123–131.

    Article  CAS  Google Scholar 

  37. De Moerloose B, Suciu S, Bertrand Y, Mazingue F, Robert A, Uyttebroeck A et al. Improved outcome with pulses of vincristine and dexamethasone in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and non Hodgkin lymphoma (NHL): final report of the EORTC randomized phase III trial 58951. Blood 2008; 112: 10a.

    Google Scholar 

  38. Hurwitz CA, Silverman LB, Schorin MA, Clavell LA, Dalton VK, Glick KM et al. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer 2000; 88: 1964–1969.

    Article  CAS  Google Scholar 

  39. Belgaumi AF, Al-Bakrah M, Al-Mahr M, Al-Jefri A, Al-Musa A, Saleh M et al. Dexamethasone-associated toxicity during induction chemotherapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycin. Cancer 2003; 97: 2898–2903.

    Article  CAS  Google Scholar 

  40. Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TO . Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 2005; 129: 734–745.

    Article  CAS  Google Scholar 

  41. Schrappe M, Zimmermann M, Moricke A, Mann G, Valsecchi MG, Bartram CR et al. Dexamethasone in induction can eliminate one third of all relapses in childhood acute lymphoblastic leukemia (ALL): results of an international trial in 3655 Patients (Trial AIEOP-BFM ALL 2000). Blood 2008; 112: 9a.

    Google Scholar 

  42. Igarashi S, Manabe A, Ohara A, Kumagai M, Saito T, Okimoto Y et al. No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol. J Clin Oncol 2005; 23: 6489–6498.

    Article  CAS  Google Scholar 

  43. Bertrand Y, Suciu S, Benoit Y, Robert A, Nelken B, Uyttebroeck L et al. Dexamethasone (DEX) (6 mg/sm/d) and prednisolone (PRED) (60 mg/sm/d) in induction therapy of childhood ALL are equally effective: results of the second interim analysis of EORTC trial 58951. Blood 2008; 112: 9a.

    Google Scholar 

  44. Cutting RJ, Richards S, Hancock J, Goulden N, Mitchell CD, Vora AJ . Post-remission MRD kinetics in children with acute lymphoblastic leukemia receiving augmented BFM consolidation compared with other regimens: results of the Medical Research Council trial UKALL 2003. Blood 2008; 112: 539a.

    Google Scholar 

  45. Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig W-D, Henze G et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group form 1981 to 19195. Leukemia 2000; 14: 2205–2222.

    Article  CAS  Google Scholar 

  46. Abromowitch M, Termuhlen A, Chang M, Perkins SL, Gross T, Weinstein HJ et al. High-dose methotrexate and early intensification of therapy do not improve 3-year EFS in children and adolescents with disseminated lymphoblastic lymphoma. results of the randomized arms of COG A5971. Blood 2008; 112: 1235a.

    Google Scholar 

  47. Winick N, Borowitz MJ, Devidas M, Martin PL, Pullen J, Hunger SP et al. Changes in delivery of standard chemotherapeutic agents during induction affect early measures of minimal residual disease (MRD): POG 9900 for patients with B-precursor low and standard risk ALL. Blood 2006; 108: 643a.

    Google Scholar 

  48. Nguyen K, Devidas M, Cheng SC, La M, Raetz EA, Carroll WL et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia 2008; 22: 2142–2150.

    Article  CAS  Google Scholar 

  49. Freyer DR, Seibel NL, La MK, Devidas M, Carroll WL, Hunger SP et al. Survival after relapse in higher risk acute lymphoblastic leukemia (ALL) in children and adolescents Is independent of prior treatment intensity: a report from the Children′s Oncology Group (COG). Blood 2008; 112: 340a.

    Article  Google Scholar 

  50. Nachman J, Siebel N, Sather H, Steinherz P, DeLaat C, Fryer D et al. Outcome for adolescent and young adults 16-21 years of age (AYA) with acute lymphoblastic leukemia (ALL) treated on the Children's Cancer Group (CCG) 1961 study. Blood 2004; 104: 683a.

    Google Scholar 

  51. Bhatia S, Francisco L, Carter A, Sun C, Baker K, Gurney J et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007; 110: 3784–3792.

    Article  CAS  Google Scholar 

  52. Ramanujachar R, Richards S, Hann I, Goldstone A, Mitchell C, Vora A et al. Adolescents with acute lymphoblastic leukaemia: outcome on UK National Paediatric (ALL97) and Adult (UKALLXII/E2993) Trials. Pediatr Blood Cancer 2007; 48: 254–261.

    Article  Google Scholar 

  53. Kadan-Lottick N, Dinu I, Wasilewski-Masker K, Kaste S, Meacham L, Mahajan A et al. Osteonecrosis in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2008; 26: 3038–3045.

    Article  Google Scholar 

  54. Mattano Jr L, Sather H, Trigg M, Nachman J . Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J Clin Oncol 2000; 18: 3262–3272.

    Article  Google Scholar 

  55. Mattano L, Sather H, La M, Nachman J, Seibel N . Modified dexamethasone (DXM) reduces the incidence of treatment-related osteonecrosis (ON) in children and adolescents with higher risk acute lymphoblastic leukemia (HR ALL): a report of CCG-1961. Blood 2003; 102: 221a.

    Google Scholar 

  56. Mattano Jr LA, Nachman JB, Devidas M, Winick N, Raetz E, Carroll WL et al. Increased incidence of osteonecrosis (ON) with a dexamethasone (DEX) induction for high risk acute lymphoblastic leukemia (HR-ALL): a report from the Children's Oncology Group (COG). Blood 2008; 112: 898a.

    Google Scholar 

  57. Mont M, Jones L, Seyler T, Marulanda G, Saleh K, Delanois R . New treatment approaches for osteonecrosis of the femoral head: an overview. Instr Course Lect 2007; 56: 197–212.

    Google Scholar 

  58. Ribeiro R, Fletcher B, Kennedy W, Harrison P, Neel M, Kaste S et al. Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma. Leukemia 2001; 15: 891–897.

    Article  CAS  Google Scholar 

  59. Gaynon PS, Bostrom BC, Hutchinson RJ, Lange BJ, Nachman JB, Steinherz PG et al. Duration of hospitalization as a measure of cost on Children's Cancer Group acute lymphoblastic leukemia studies. J Clin Oncol 2001; 19: 1916–1925.

    Article  CAS  Google Scholar 

  60. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 2008; 111: 5477–5485.

    Article  CAS  Google Scholar 

  61. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, Van der Velden V, Fischer S et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-receptor gene rerearragnements in the international multicenter trialAIEOP BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008; 22: 771–782.

    Article  CAS  Google Scholar 

  62. Willemse MJ, Seriu T, Hettinger K, d'Aneillo E, Hop WCJ, Panzer-Grümayer ER et al. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood 2002; 99: 4386–4393.

    Article  CAS  Google Scholar 

  63. Bhojwani D, Kang H, Menezes RX, Yang W, Sather H, Moskowitz NP et al. Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: a Children's Oncology Group Study [corrected]. J Clin Oncol 2008; 26: 4376–4384.

    Article  CAS  Google Scholar 

  64. Mullighan CG, Phillips LA, Su X, Ma J, Miller CB, Shurtleff SA et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008; 322: 1377–1380.

    Article  CAS  Google Scholar 

  65. Mullighan C, Su X, Zhang J, Radtke I, Phillips L, Miller C et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J of Med 2009; 360: 470–480.

    Article  CAS  Google Scholar 

  66. Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2009; 106: 9414–9418.

    Article  CAS  Google Scholar 

  67. Cheok M, Evans W . Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 2006; 6: 117–129.

    Article  CAS  Google Scholar 

  68. Pritchard M, Butow P, Stevens M, Duley J . Understanding medication adherence in pediatric acute lymphoblastic leukemia: a review. J Pediatr Hematol Oncol 2006; 28: 816–823.

    Article  CAS  Google Scholar 

  69. O'Brien S, Guilhot F, Larson R, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J of Med 2003; 348: 994–1004.

    Article  CAS  Google Scholar 

  70. Schultz KR, Bowman WP, Slayton W, Aledo A, Devidas M, Sather H et al. Improved early event free survival (EFS) in children with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) with imatinib in combination with high dose chemotherapy: Children's Oncology Group (COG) study AALL0031. J Clin Oncol 2009; 27: 5175–5181.

    Article  CAS  Google Scholar 

  71. Hochhaus A . Management of Bcr-Abl-positive leukemias with dasatinib. Expert Rev Anticancer Ther 2007; 7: 1529–1536.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Research is supported by the Chair's Grant U10 CA98543 and the Statistics and Data Center Grant U10 CA98413 of the Children's Oncology Group from the National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to P S Gaynon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gaynon, P., Angiolillo, A., Carroll, W. et al. Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983–2002: A Children's Oncology Group Report. Leukemia 24, 285–297 (2010). https://doi.org/10.1038/leu.2009.262

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2009.262

Keywords

This article is cited by

Search

Quick links